medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher Advanced Glycation End-products (AGEs) content and reduced bone strength

Giulia Leanza MSc, PhD[1,2], Francesca Cannata MSc, PhD[1], Malak Faraj MSc[1], Claudio Pedone MD, PhD[3], Viola Viola MSc[1], Flavia Tramontana MSc, PhD[1,2], Niccolò Pellegrini MSc[1], Gianluca Vadalà, MD, PhD[4], Alessandra Piccoli PhD[1], Rocky Strollo MD, PhD[5], Francesca Zalfa, MSc, PhD[6,7], Alec Beeve PhD[8], Erica L Scheller DDS, PhD[8], Simon Tang PhD[9], Roberto Civitelli MD[8], Mauro Maccarrone PhD[10,11], Rocco Papalia MD, PhD[4,*†] and Nicola Napoli MD, PhD [1,2,8*†]

[1] Department of Medicine and Surgery, Research Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy;
[2] Operative Research Unit of Osteometabolic and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy;
[3] Operative Research Unit of Geriatrics, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy;
[4] Operative Research Unit of Orthopedic and Trauma Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy;
[5] Department of Human Sciences and Promotion of the Quality of Life San Raffaele Roma Open University Via di Val Cannuta 247, 00166 Roma, Italy
[6] Predictive Molecular Diagnostic Unit, Pathology Department, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 – 00128, Roma, Italy;
[7] Microscopic and Ultrastructural Anatomy Unit, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Roma, Italy
[8] Department of Medicine, Division of Bone and Mineral Diseases. Musculoskeletal Research Center, Washington University School of Medicine, St. Louis, MO USA;
[9] Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, MO, USA;
[10] Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio snc, 67100 L'Aquila, Italy;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

[11] European Center for Brain Research, Santa Lucia Foundation IRCCS, 00164 Roma, Italy

† These authors are equally senior authors.

***Corresponding Authors*:**

Nicola Napoli, MD PhD

Department of Medicine and Surgery

Research Unit of Endocrinology and Diabetes

Università Campus Bio-Medico di Roma

Via Alvaro del Portillo 21

00128 Roma, Italy

n.napoli@unicampus.it

Rocco Papalia, MD PhD

Operative Research Unit of Orthopedic and Trauma Surgery

Fondazione Policlinico Campus Bio-Medico di Roma

Via Alvaro del Portillo 200

00128 Roma, Italy

r.papalia@fondazionepoliclinico.it

***Short title*:** Wnt signaling in bone of type 2 diabetes

Keywords: Diabetes, Bone, Wnt signaling, AGEs

Disclosures

All authors have nothing to disclose relevant to this work.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Abstract

Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral density. We reported that bone formation genes (*SOST* and *RUNX2*) and Advanced Glycation End-products (AGEs) were impaired in T2D. We investigated Wnt signaling regulation and its association with AGEs accumulation and bone strength in T2D from bone tissue of 15 T2D and 21 non-diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a trend of low mineralized volume in T2D [(T2D 0.249% (0.156-0.366) vs non-diabetic subjects 0.352% (0.269-0.454); p=0.053)], as well as reduced bone strength [T2D 21.60 MPa (13.46-30.10) vs non-diabetic subjects 76.24 MPa (26.81-132.9); p=0.002]. We also showed that gene expression of Wnt agonists *LEF-1* (p=0.0136) and *WNT10B* (p=0.0302) were lower in T2D. Conversely, gene expression of *WNT5A* (p=0.0232), *SOST* (p<0.0001) and *GSK3B* (p=0.0456) were higher, while collagen (*COL1A1*) was lower in T2D (p=0.0482). AGEs content was associated with *SOST* and *WNT5A* (r=0.9231, p<0.0001; r=0.6751, p=0.0322), but inversely correlated with *LEF-1* and *COL1A1* (r= -0,7500, p=0.0255; r= -0,9762, p=0.0004). *SOST* was associated with glycemic control and disease duration (r=0.4846, p=0.0043; r=0.7107, p=0.00174), whereas *WNT5A* and *GSK3B* were only correlated with glycemic control (r=0.5589, p=0.0037; r=0.4901, p=0.0051). Finally, Young's Modulus was negatively correlated with *SOST* (r=-0.5675, p=0.0011), *AXIN2* (r=-0.5523, p=0.0042) and *SFRP5* (r=-0.4442, p=0.0437), while positively correlated with *LEF -1* (r=0.4116, p=0.0295) and *WNT10B* (r=0.6697, p=0.0001). These findings suggest that Wnt signaling, and AGEs could be the main determinants of bone fragility in T2D.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Graphical abstract



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Introduction

Type 2 diabetes (T2D) is a metabolic disease, with an increasing worldwide prevalence, characterized by chronic hyperglycemia and adverse effects on multiple organ systems, including bones [1]. Patients with T2D have an increased fracture risk, particularly at the hip, compared to individuals without diabetes. A recent meta-analysis reported that individuals with T2D have 1.27 relative risk (RR) of hip fracture compared to non-diabetic controls [2]**.** Fragility fractures in patients with T2D occur at normal or even higher bone mineral density compared to healthy subjects, implying compromised bone quality in diabetes. T2D is associated with a reduced bone turnover [3], as shown by lower serum levels of biochemical markers of bone formation, such as procollagen type1 amino-terminal propeptide (P1NP) and osteocalcin, and bone resorption, C-terminal cross-linked telopeptide (CTX) in diabetic patients compared to nondiabetic individuals [4–7]. Accordingly, dynamic bone histomorphometry of T2D postmenopausal women showed a lower bone formation rate, mineralizing surface, osteoid surface, and osteoblast surface[8]. Our group recently demonstrated that T2D is also associated with increased *SOST* and decreased *RUNX2* genes expression, compared to non-diabetic subjects[9]. Moreover, we have proved in a diabetic model that a sclerostin-resistant *Lrp5* mutation, associated with high bone mass, fully protected bone mass and strength even after prolonged hyperglycemia [10]. Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway, a key pathway that regulates bone homeostasis [11]**.**

Diabetes and chronic hyperglycemia are also characterized by increased advanced glycation end-products (AGEs) production and deposition [12]. AGEs may interfere with osteoblast differentiation, attachment to the bone matrix, function, and survival [13,14]. AGEs also alter bone collagen structure and reduce the intrinsic toughness of bone, thereby affecting bone

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

material properties [9,15,16]. In this work,we hypothesized that T2D and AGEs accumulation downregulate Wnt canonical signaling and negatively affect bone strength.. Results confirmed that T2D downregulates Wnt beta/catenin signaling and reduces collagen mRNA levels and bone strength, in association with AGEs accumulation.

Materials and Methods

Study subjects

We enrolled a total of 36 postmenopausal women (15 with T2D and 21 non-diabetic controls) undergoing hip arthroplasty for osteoarthritis, consecutively screened to participate in this study between 2020 and 2022. Diabetes status was confirmed by the treating diabetes physician. Participants were diagnosed with diabetes when they had fasting plasma glucose (FPG) ≥126 mg/dl or 2-h plasma glucose (2-h PG) ≥200 mg/dl during a 75-g oral glucose tolerance test (OGTT); or hemoglobin A1c (HbA1c) ≥6.5% in accordance with the American Diabetes Association diagnostic criteria. Eligible participants were ≥60 years of age. Exclusion criteria were any diseases affecting bone or malignancy. Additionally, individuals treated with medications affecting bone metabolism such as estrogen, raloxifene, tamoxifen, bisphosphonates, teriparatide, denosumab, thiazolidinediones, glucocorticoids, anabolic steroids, and phenytoin, and those with hypercalcemia or hypocalcemia, hepatic or renal disorder, hypercortisolism, current alcohol or tobacco use were excluded. The study was approved by the Ethics Committee of the Campus Bio-Medico University of Rome and all participants provided written informed consent. All procedures were conducted in accordance with the Declaration of Helsinki.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Specimen preparation

Femoral head specimens were obtained during hip arthroplasty. As described previously [9], trabecular bone specimens were collected fresh and washed multiple times in sterile PBS until the supernatant was clear of blood. Bone samples were stored at – 80 °C until analysis.

Bone histomorphometry

Trabecular bone from femur heads werefixed in 10% neutral buffered formalin for 24 h prior to storage in 70% ethanol. Tissues were embedded in methylmethacrylate and sectioned sagittally by the Washington University Musculoskeletal Histology and Morphometry Core. Sections were stained with Goldner's trichrome. Then, a rectangular region of interest containing trabecular bone was chosen below the cartilage-lined joint surface and primary spongiosa. This region had an average dimension of 45 mm^2. Tissue processing artifacts, such as folding and edges, were excluded from the ROI. A threshold was chosen using the Bioquant Osteo software to automatically select trabeculae and measure bone volume. Finally, Osteoid was highlighted in the software and quantified semi-automatically using a threshold and correcting with the brush tool. Unstained and TRAP-stained (Sigma) slides were imaged at ×20 high resolution using a NanoZoomer 2.0 with bright field and FITC/TRITC (Hamamatsu Photonics). Images were then analyzed via Bioquant Osteo software according to the manufacturer's instructions and published standards (v18.2.6, Bioquant Image Analysis Corp., Nashville, TN).

Bone compression tests

We used cylindrical bone specimens of trabecular core (with a diameter of 10 mm and a length of 20 mm) from 10 T2D and 21 non-diabetic subjects to measure bone mechanical parameters (Young's modulus, ultimate strength and yield strength), as previously described [9].

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

RNA extraction and gene expression by RT-PCR

Total RNA from trabecular bone samples was extracted using TRIzol (Invitrogen) following the manufacturer's instructions. The concentration and purity of the extracted RNA were assessed spectrophotometrically (TECAN, InfiniteM200PRO), and only samples with 260/280 absorbance ratio between 1.8 and 2 were used for reverse transcription using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) according to the manufacturer's recommendations. Transcription products were amplified using TaqMan real-time PCR (Applied Biosystems, Carlsbad, CA) and a standard protocol (95°C for 10 minutes; 40 cycles of 95°C for 15 seconds and 60°C for 1 minute; followed by 95°C for 15 seconds, 60°C for 15 seconds, and 95°C for 15 seconds). β-Actin expression was used as an internal control (housekeeping gene). Relative expression levels of Sclerostin (*SOST*), Dickkopf-1 (*DKK-1*), Wnt ligands (*WNT5A* and *WNT10B*), T-cell factor/ lymphoid enhancer factor 1 (*LEF-1*), collagen type I alpha 1 chain (*COL1A1*), glycogen synthase kinase 3 beta (*GSK3B*), axis inhibition protein 2 (*AXIN2*), beta-catenin (*BETA-CATENIN*) and secreted frizzled-related protein 5 (*SFRP5*) were calculated using the $2^{-\Delta Ct}$ method.

Statistical analysis

Data were analyzed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA). Patients' characteristics were described using means and standard deviations or medians and 25th-75th percentiles, as appropriate, and percentages. Group data are presented in boxplots with median and interquartile range; whiskers represent maximum and minimum values. We assessed data for normality and Mann-Whitney test was used to compare variables between groups. Data were analyzed using nonparametric Spearman correlation analysis and the correlation coefficients (r)

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

were used to assess the relationship between variables. We used Grubbs' Test to assess and exclude outliers.

RESULTS

Subject characteristics

Clinical characteristics of study subjects are presented in Table 1. T2D and non-diabetic subjects did not differ in age, BMI and menopausal age. As expected, fasting glucose was significantly higher in T2D compared to non-diabetic subjects [112.00 mg/dl (104.0-130.0) mg/dl, *vs.* 94.00 (87.2-106.3), respectively; p=0.009]. Median HbA1c was determined in all T2D subjects within three months before surgery [(6.95% (6.37-7.37)]. Median disease duration in T2D subjects was [14.50 years (7.25-19.25)]. Diabetes medications included monotherapy with metformin (n=12) and combination therapy with metformin plus insulin and glinide (n=3). There were no differences in serum calcium, eGFR (CKD-EPI equation) and serum blood urea nitrogen.

Bone Histomorphometry

Bone samples of 8 T2D and 9 non-diabetic subjects were used for histomorphometry analysis. We found no significant differences in BV/TV and osteoid volume, while mineralized volume/total volume (Md.V/TV) trended lower in T2D subjects relative to controls [0.249% (0.156-0.336) vs 0.352% (0.269-0.454); p=0.053] (Table 2).

Bone compression tests

Young’s modulus was lower in T2D compared to non-diabetic subjects [21.6 MPa (13.46-30.10) vs. 76.24 MPa (26.81-132.9); p=0.0025), while ultimate strength and yield strength were not different between the two groups (Table 3).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Gene Expression

SOST mRNA was significantly higher in T2D than in non-diabetic subjects (Fig. 1A, p<0.0001), whereas there was no difference in *DKK1* gene expression between the two groups (Fig. 1B). Of note, *SOST* mRNA transcript was very low in the majority of non-diabetic subjects (Fig. 1A). *LEF-1* (Fig. 1C, p=0.0136), *WNT10B (Fig. 1D*, p=0.0302) and *COL1A1* (Fig.1F, p=0.0482) mRNA transcripts were significantly lower in T2D compared to non-diabetic subjects. Conversely, *WNT5A* was higher in T2D relative to non-diabetics (Fig. 1E, p=0.0232). Moreover, *GSK3B* was significantly increased in T2D compared to non- diabetic subjects (Fig.1G, p=0.0456), but we did not find any significant difference in gene expression of *AXIN2*, *BETA-CATENIN* and *SFRP5* (Fig. 1H-J) between our groups.

Correlation analysis of Wnt target genes, AGEs and glycemic control

As shown in figure 2, AGEs were inversely correlated with *LEF-1* (Fig. 2A, p=0.0255) and *COL1A1* mRNA abundance (Fig. 2B, p=0.0004), whereas they were positively correlated with *SOST* (Fig. 2C, p<0.0001) and *WNT5A* mRNA (Fig. 2D, p=0.0322). There was no correlation between AGEs content and *WNT10B* (Fig. 2E; p=0.1938) or *DKK1* gene expression (Fig. 2F; p=0.9349). Likewise, we did not find any significant correlation between *LEF-1*, *WNT5A*, *WNT10B*, *DKK-1*, *COL1A1* expression in bone and glycemic control in T2D individuals (Supplemental Figure 1A-D). However, there were positive correlations between *SOST* and fasting glucose levels (Fig. 3A, p=0.0043), *SOST* and disease duration (Fig. 3B, p=0.00174), *WNT5A*, *GSK3B* and fasting glucose levels (Fig. 3C, p=0.0037; Fig. 3D, p=0.0051).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Correlation analysis of Wnt target genes and bone mechanical parameters

As shown in Figure 4, Young's Modulus was negatively correlated with *SOST* (Fig.4A, p=0.0011), *AXIN2* (Fig. 4D, p=0.0042) and *SFRP5* (Fig 4F, p=0.0437), while positively correlated with *LEF -1* (Fig. 4B, p=0.0295) and *WNT10B* (Fig. 4C, p=0.0001). Ultimate strength was associated with *WNT10B* (Fig. 4F, p=0.0054) and negatively correlated with *AXIN2* (Fig. 4G, p=0.0472). Finally, yield strength was associated with *LEF-1* (Fig. 4H, p=0.0495) and *WNT10B* (Fig. 4I, p=0.0020) and negatively correlated with *GSK3B* (Fig. 4J, p=0.0245), AXIN2 (Fig. 4K, p=0.0319), and *SFRP5* (Fig. 4L, p=0.0422). Non-significant correlations are reported in Supplementary figure 2 (A-Q).

Discussion

We show that key components of the Wnt/beta-catenin signaling are abnormally expressed in the bone of postmenopausal women with T2D and they are associated with AGEs and reduced bone strength. *LEF-1*, a transcription factor that mediates responses to Wnt signal and Wnt target genes itself, and *WNT10B*, an endogenous regulator of Wnt/β-catenin signaling and skeletal progenitor cell fate, are both downregulated in bone of postmenopausal women with T2D. Consistently, in this group, the expression of the Wnt inhibitor, *SOST* is increased, suggesting suppression of Wnt/β-catenin signaling. Interestingly, our data suggest that sclerostin expression is very low in healthy postmenopausal women not affected by osteoporosis. Moreover, we reported an increase in the expression level of bone *GSK3B*, in line with downregulated Wnt/β-catenin signaling in T2D. Our data also show that the expression of *WNT5A*, a non-canonical ligand linked to inhibition of Wnt/beta-catenin signaling was increased, whereas *COL1A1* was decreased. These findings are consistent with reduced bone formation and suppression of Wnt signaling in T2D. We have previously reported upregulation of *SOST* and downregulation of

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

RUNX2 mRNA in another cohort of postmenopausal women with T2D [9]. Of note, the cohort of T2D subjects studied here had glycated hemoglobin within therapeutic targets, implying that the changes in gene transcription we identified persist in T2D bone despite good glycemic control.

High circulating sclerostin has been reported in diabetes [17,18], and increased sclerostin is associated with fragility fractures [19]. Aside from confirming higher *SOST* expression, we also show that other Wnt/β-catenin osteogenic ligands are abnormally regulated in the bone of T2D postmenopausal women. *WNT10B* is a positive regulator of bone mass; transgenic overexpression in mice results in increased bone mass and strength [20], whereas genetic ablation of *WNT10B* is characterized by reduced bone mass [21,22], and decreased number and function of osteoblasts [21]. More to the point, *WNT10B* expression is reduced in the bone of diabetic mice [23]. Therefore, the reduced *WNT10B* in human bone we found in the present study further supports the hypothesis of reduced bone formation in T2D. Accordingly, *LEF-1* gene expression was also downregulated confirming that Wnt/beta-catenin pathway is decreased in T2D. Importantly, the overexpression of *LEF-1* induces the expression of osteoblast differentiation genes (osteocalcin and *COL1A1*) in differentiating osteoblasts [24]. In fact, in this study we also demonstrated that a downregulation of *LEF-1* in T2D bone goes along with a downregulation of *COL1A1*, strengthen data of a reduced production of bone matrix most likely as the result of reduced osteoblasts synthetic activity in diabetes [8,25]. Reduced *RUNX2* in T2D postmenopausal women also confirms previous findings [9] and further supports the notion of reduced osteoblast differentiation or function in diabetes. On the other hand, the contribution of upregulated *WNT5A* in diabetic bone is more complex. *WNT5A* regulates Wnt/beta-catenin signaling depending on the receptor availability [26]. Non-canonical *WNT5A* activates β-catenin-independent signaling, including the Wnt/Ca^{++} [27] and planar cell polarity pathways [28].

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Heterozygous Wnt5a null mice have low bone mass with impaired osteoblast and osteoclast differentiation [29]. Wnt5a inhibits Wnt3a protein by downregulating beta/catenin-induced reporter gene expression [26]. In line with these findings, we showed that there was an increased gene expression of *WNT5A* in bone of T2D postmenopausal women, confirming a downregulated Wnt/beta-catenin signaling and impaired osteoblasts function. Moreover, *GSK3B* is a widely expressed serine/threonine kinase involved in multiple pathways regulating immune cell activation and glucose metabolism. Preclinical studies reported that *GSK3B* is a negative regulator of Wnt/beta-catenin signaling and bone metabolism [30,31], and its increase is associated with T2D and alterations in insulin secretion and sensitivity [32,33]. Our data, confirmed that *GSK3B* is increased in T2D postmenopausal women and it is associated with reduced yield strength. In fact, we also showed an impaired bone mechanical plasticity in T2D, in line with other studies showing a reduced bone strength [16,34,35]. In addition, this study reported significant correlations of bone mechanical parameters and Wnt target genes, which might reflect the biological effect of downregulated Wnt signaling and AGEs accumulation on bone mechanical properties in diabetes.

We have previously shown that AGEs content is higher in T2D bone compared to non-diabetic bone, even in patients with well-controlled T2D [9]. Here we show that AGEs accumulation is positively correlated with *SOST*, *WNT5A* and *GSK3B* gene expression, and negatively correlated with *LEF-1*, *WNT10B*, and *COL1A1* mRNA. These findings are consistent with the hypothesis that AGEs accumulation is associated with impaired Wnt signaling and low bone turnover in T2D. We did not find any abnormalities in histomorphometric parameters in our subjects with T2D, consistent with our previous report [9]. Reduced osteoid thickness and osteoblast number were reported in premenopausal T2D women with poor glycemic control compared to non-

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

diabetic subjects but not in the group with good glycemic control [36]. Therefore, good glycemic control appears to prevent or rescue any changes in static histologic parameters of bone turnover that might be caused by uncontrolled diabetes.

Our study has some limitations. One is the cross-sectional design; another one is the relatively small number of T2D subjects enrolled. Moreover, we measured the mRNA abundance of the genes of interest, and we cannot assume that the differences we found reflect differences in protein abundance. Although osteoarthritis may affect some of the genes we studied [37], all study subjects were affected by variable degree of osteoarthritis, and the effect of such potential confounder is not likely to be different between T2D and control subjects. Finally, we did not use the tetracycline double-labeled technique to investigate dynamic bone parameters.

The main strength of our study is that this study is the first to explore the association of AGEs on Wnt pathway in postmenopausal T2D women. Moreover, we measured the expression of several Wnt genes directly on bone samples of postmenopausal T2D women.

In conclusion, our data show that, despite good glycemic control, T2D decreases expression of *COL1A1* and Wnt genes that regulate bone turnover, in association with increased AGEs content and reduced bone strength. These results may help understand the mechanisms underlying bone fragility in T2D.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Acknowledgements

This work was supported by an internal Grant of Campus Bio-Medico University of Rome.

Author Contributions: Conceptualization, N.N, R.P., M.M and R.S.; methodology, G.L., F.C., M.F., V.V., F.T., N.P., A.B., S.T..; software, G.L., C.P., A.B., and E.S.; validation, N.N. and G.L.; formal analysis, N.N. and G.L.; investigation, N.N., R.S., M.M. and R.P.; resources, N.N, G.V., R.P. M.M., and R.S.; data curation, G.L. and N.P..; writing—original draft preparation, G.L., M.F., N.P., R.C. and N.N.; writing—review and editing, G.L., N.N., C.P., N.P., F.Z., E.S., R.S. and R.C.; visualization, N.N. and R.S..; supervision, N.N., R.P., and M.M.; project administration, N.N. and G.L.; funding acquisition, N.N. and R.S. All authors have read and agreed to the published version of the manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

References

[1] Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, Müller R, et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 2022;10:207–20. https://doi.org/10.1016/S2213-8587(21)00347-8.

[2] Wang H, Ba Y, Xing Q, Du J-L. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open 2019;9:e024067. https://doi.org/10.1136/bmjopen-2018-024067.

[3] Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res 2016;4:16001. https://doi.org/10.1038/boneres.2016.1.

[4] Napoli N, Strollo R, Defeudis G, Leto G, Moretti C, Zampetti S, et al. Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults. J Clin Endocrinol Metab 2018;103:1921–8. https://doi.org/10.1210/jc.2017-02274.

[5] Hygum K, Starup-Linde J, Harsløf T, Vestergaard P, Langdahl BL. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. Eur J Endocrinol 2017;176:R137–57. https://doi.org/10.1530/EJE-16-0652.

[6] Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone 2016;82:69–78. https://doi.org/10.1016/j.bone.2015.02.019.

[7] Starup-Linde J, Lykkeboe S, Gregersen S, Hauge E-M, Langdahl BL, Handberg A, et al. Differences in biochemical bone markers by diabetes type and the impact of glucose.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Bone 2016;83:149–55. https://doi.org/10.1016/j.bone.2015.11.004.

[8] Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:3240–50. https://doi.org/10.1210/jc.2012-1546.

[9] Piccoli A, Cannata F, Strollo R, Pedone C, Leanza G, Russo F, et al. Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes. J Bone Miner Res 2020;35:2415–22. https://doi.org/10.1002/jbmr.4153.

[10] Leanza G, Fontana F, Lee S-Y, Remedi MS, Schott C, Ferron M, et al. Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes. J Bone Miner Res 2021;36:1403–15. https://doi.org/10.1002/jbmr.4303.

[11] Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, et al. The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci 2019;20. https://doi.org/10.3390/ijms20225525.

[12] Tan KCB, Chow W-S, Ai VHG, Metz C, Bucala R, Lam KSL. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002;25:1055–9. https://doi.org/10.2337/diacare.25.6.1055.

[13] Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 2005;20:1647–58. https://doi.org/10.1359/JBMR.050514.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

[14] Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008;1126:166–72. https://doi.org/10.1196/annals.1433.044.

[15] Yamamoto M, Sugimoto T. Advanced Glycation End Products, Diabetes, and Bone Strength. Curr Osteoporos Rep 2016;14:320–6. https://doi.org/10.1007/s11914-016-0332-1.

[16] Furst JR, Bandeira LC, Fan W-W, Agarwal S, Nishiyama KK, McMahon DJ, et al. Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. J Clin Endocrinol Metab 2016;101:2502–10. https://doi.org/10.1210/jc.2016-1437.

[17] García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:234–41. https://doi.org/10.1210/jc.2011-2186.

[18] Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012;97:1737–44. https://doi.org/10.1210/jc.2011-2958.

[19] Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013;98:4030–7. https://doi.org/10.1210/jc.2013-2143.

[20] Longo KA, Wright WS, Kang S, Gerin I, Chiang S-H, Lucas PC, et al. Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem 2004;279:35503–9. https://doi.org/10.1074/jbc.M402937200.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

[21] Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 2005;102:3324–9. https://doi.org/10.1073/pnas.0408742102.

[22] Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009;27:265–71. https://doi.org/10.1007/s00774-009-0064-8.

[23] Zhang J, Motyl KJ, Irwin R, MacDougald OA, Britton RA, McCabe LR. Loss of Bone and Wnt10b Expression in Male Type 1 Diabetic Mice Is Blocked by the Probiotic Lactobacillus reuteri. Endocrinology 2015;156:3169–82. https://doi.org/10.1210/EN.2015-1308.

[24] Hoeppner LH, Secreto F, Jensen ED, Li X, Kahler RA, Westendorf JJ. Runx2 and bone morphogenic protein 2 regulate the expression of an alternative Lef1 transcript during osteoblast maturation. J Cell Physiol 2009;221:480–9. https://doi.org/10.1002/jcp.21879.

[25] Khan MP, Singh AK, Joharapurkar AA, Yadav M, Shree S, Kumar H, et al. Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes 2015;64:2609–23. https://doi.org/10.2337/db14-1611.

[26] Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006;4:e115. https://doi.org/10.1371/journal.pbio.0040115.

[27] Dejmek J, Säfholm A, Kamp Nielsen C, Andersson T, Leandersson K. Wnt-5a/Ca2+-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

signaling in human mammary epithelial cells. Mol Cell Biol 2006;26:6024–36. https://doi.org/10.1128/MCB.02354-05.

[28] Oishi I, Suzuki H, Onishi N, Takada R, Kani S, Ohkawara B, et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cells 2003;8:645–54. https://doi.org/10.1046/j.1365-2443.2003.00662.x.

[29] Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 2012;18:405–12. https://doi.org/10.1038/nm.2653.

[30] McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J 2005;24:1571–83. https://doi.org/10.1038/sj.emboj.7600633.

[31] Chen Y, Chen L, Huang R, Yang W, Chen S, Lin K, et al. Investigation for GSK3β expression in diabetic osteoporosis and negative osteogenic effects of GSK3β on bone marrow mesenchymal stem cells under a high glucose microenvironment. Biochem Biophys Res Commun 2021;534:727–33. https://doi.org/10.1016/j.bbrc.2020.11.010.

[32] Nunez Lopez YO, Iliuk A, Petrilli AM, Glass C, Casu A, Pratley RE. Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23105779.

[33] Xia H, Scholtes C, Dufour CR, Ouellet C, Ghahremani M, Giguère V. Insulin action and resistance are dependent on a GSK3β-FBXW7-ERRα transcriptional axis. Nat Commun 2022;13:2105. https://doi.org/10.1038/s41467-022-29722-6.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

[34] Farr JN, Drake MT, Amin S, Melton LJ, McCready LK, Khosla S. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014;29:787–95. https://doi.org/10.1002/jbmr.2106.

[35] Hunt HB, Torres AM, Palomino PM, Marty E, Saiyed R, Cohn M, et al. Altered Tissue Composition, Microarchitecture, and Mechanical Performance in Cancellous Bone From Men With Type 2 Diabetes Mellitus. J Bone Miner Res 2019;34:1191–206. https://doi.org/10.1002/jbmr.3711.

[36] Andrade VFC, Chula DC, Sabbag FP, Cavalheiro DD da S, Bavia L, Ambrósio AR, et al. Bone Histomorphometry in Young Patients With Type 2 Diabetes is Affected by Disease Control and Chronic Complications. J Clin Endocrinol Metab 2020;105. https://doi.org/10.1210/clinem/dgz070.

[37] Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the osteocyte. Bone 2017;96:45–50. https://doi.org/10.1016/j.bone.2016.11.024.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Table 1. Clinical features of the study subjects

	T2D subjects (n=15)	Non-diabetic subjects (n=21)	P value
Age (years)	73.00 (67.00-80.00)	73.00 (68.50-79.00)	0.644
BMI (kg/m^2)	30.81 (24.44-34.00)	25.00 (24.00-31.50)	0.117
Menopausal age (years)	50.00 (42.50-52.75)	52.00 (48.00-53.00)	0.344
Fasting glucose levels (mg/dl)	112.00 (104.00-130.0)	94.00 (87.25-106.3)	**0.009
Disease duration (years)	14.50 (7.25-19.25)	-	-
HbA1c (%)	6.95 (6.37-7.37)	-	-
Serum calcium (mg/dl)	9.05 (8.800-9.550)	9.15 (9.000-9.550)	0.535
eGFR (mL/min/1.73 m^2)	78,30 (59.90-91.10)	75.60 (61.35-88.55)	0.356
Serum blood urea nitrogen (mg/dl)	42.00 (36.00-53.00)	37.00 (31.75-46.50)	0.235

Table 1. Results were analyzed using unpaired T-test with Welch's correction. Results are presented as median and percentiles (25th and 75th).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Table 2. Histomorphometric parameters of trabecular bone of the study subjects

	T2D subjects (n=8)	Non-diabetic subjects (n=9)	P value
BV/TV (%)	0.248 (0.157-0.407)	0.358 (0.271-0.456)	0.120
Md.V/BV (%)	0.994(0.984-0.998)	0.995 (0.985-0.997)	0.998
Md.V/TV (%)	0.249 (0.156-0.366)	0.352 (0.269-0.454)	0.053
OV/BV (%)	0.009 (0.002-0.009)	0.004 (0.002-0.015)	0.704
OV/TV (%)	0.001 (0.0002-0.0058)	0.001 (0.0007-0.0056)	0.896
OS/BS (%)	0.026 (0.022-0.161)	0.035 (0.009-0.117)	0.525

Table 2. Results were analyzed using unpaired T-test with Welch's correction and are presented as median and percentiles (25th and 75th).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Table 3. Bone mechanical parameters of trabecular bone of the study subjects

	T2D subjects (n=10)	**Non-diabetic subjects (n=21)**	**P value**
Young's modulus (MPa)	21.60 (13.46-30.10)	76.24 (26.81-132.9)	0.002
Ultimate strength (MPa)	3.015 (2.150-13,86)	7.240 (3.150-8.898)	0.914
Yield strength (MPa)	2.525 (1.943-6.393)	6.150 (3.115-7.423)	0.159

Table 3. Results were analyzed using unpaired T-test with Welch's correction and are presented as median and percentiles (25th and 75th).

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure 1.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure 2.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure 3.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure 4.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Figure Legends

Figure 1. Gene expression analysis in trabecular bone samples. (A) SOST mRNA levels resulted higher in T2D subjects versus Nondiabetic subjects (p<0.0001). (B) DKK-1 mRNA expression level was not different between groups (p=0.2022). (C) LEF-1 mRNA levels resulted lower in T2D subjects versus nondiabetics subjects (p=0.0136). (D) WNT10B mRNA expression level was lower in T2D subjects versus nondiabetic subjects (p=0.0302). (E) WNT5A mRNA resulted higher in T2D subjects versus nondiabetics subjects (p=0.0232). (F) COL1A1 mRNA levels resulted lower in T2D subjects versus Nondiabetic subjects (p=0.0482). (G) GSK3B mRNA levels resulted higher in T2D subjects versus Nondiabetic subjects (p=0.0456). (H-J) AXIN2, BETA-CATENIN, SFRP5 mRNA levels were not different between groups (p=0.2296, p=0.3073; p=0.1390). Data are expressed as fold changes over beta-actinMedians and interquartile ranges, differences between non-diabetics and T2D subjects were analyzed using Mann-Whitney test.

Figure 2. Relationship between AGEs (µg quinine/g collagen) bone content and mRNA level of the Wnt signaling key genes in T2D and non-diabetic subjects. (A) LEF-1 negatively correlated with AGEs (r=-0.7500; p=0.0255). (B) COL1A1 negatively correlated with AGEs (r=-0.9762; p=0.0004). (C) SOST mRNA level expression positively correlated with AGEs (r=0.9231; p<0.0001). (D) WNT5A mRNA expression level positively correlated with AGEs (r=0.6751; p=0.0322). (E) WNT10B mRNA expression level was not correlated with AGEs (r=-0.4883; p=0.1938). (F) DKK1 mRNA expression level was not correlated with AGEs (r=0.0476; p=0.9349). (G) GSK3B mRNA expression level was positively correlated with AGEs (r=0.7500; p=0.0255). (H) SFRP5 mRNA expression level was positively correlated with AGEs (r=0.7167; p=0.0369). (I) AXIN2 and (J) SFRP5 mRNA expression levels were not correlated with AGEs

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

(r=0.5500, p=0.1328; r=0.2167, p=0.5809). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.

Figure 3. Relationship between fasting glucose levels (mg/dl) and disease duration with SOST and WNT5A mRNA levels. (A) SOST positively correlated with fasting glucose levels (r=0.4846; p=0.0043). (B) SOST positively correlated with disease duration (r=0.7107; p=0.0174). (C) WNT5A positively correlated with fasting glucose levels (r=0.5589; p=0.0037). (D) GSK3B positively correlated with fasting glucose levels (r=0.4901; p=0.0051). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.

Figure 4. Relationship between Young Modulus (MPa), Ultimate strength (MPa) and Yield strength (MPa) with mRNA levels of the Wnt signaling key genes in T2D and non-diabetic subjects. (A) SOST negatively correlated with Young Modulus (MPa); (r=-0.5675; p=0.0011). (B) LEF-1 positively correlated with Young Modulus (MPa); (r=0.4116; p=0.0295). (C) WNT10B positively correlated with Young Modulus (MPa); (r=0.6697; p=0.0001). (D) AXIN2 negatively correlated with Young Modulus (MPa); (r=-0.5523; p=0.0042). (E) BETA-CATENIN negatively correlated with Young Modulus (MPa); (r=-0.5244; p=0.0050). (F) SFRP5 negatively correlated with Young Modulus (MPa); (r=-0.4442; p=0.0437). (G) WNT10B positively correlated with Ultimate strength (MPa); (r=0.5392; p=0.0054). (H) AXIN2 negatively correlated with Ultimate strength (MPa); (r=-0.4180; p=0.0472). (I) BETA-CATENIN negatively correlated with Ultimate strength (MPa); (r=-0.5528; p=0.0034). (J) LEF-1 positively correlated with Yield strength (MPa); (r=0.4338; p=0.0495). (K) WNT10B positively correlated with Yield strength (MPa); (r=0.6632; p=0.0020). (L) GSK3B negatively correlated with Yield strength (MPa); (r=-0.4674; p=0.0245). (M) AXIN2 negatively correlated with Yield strength

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

(MPa); (r=-0.5067; p=0.0319). (N) BETA-CATENIN negatively correlated with Yield strength (MPa); (r=-0.5491; p=0.0149). (O) SFRP5 negatively correlated with Yield strength (MPa); (r=-0.5357; p=0.0422). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.

Supplementary figure 1.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Supplementary figure 2.



medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Legend of supplementary figures

Supplementary figure 1. Relationship between fasting glucose levels (mg/dl) and LEF-1, WNT5A, WNT10B, DKK-1, COL1A1 mRNA levels. (A-E) Data showed negative correlations between fasting glucose levels (mg/dl) and (A) LEF-1 (r=-0.3649; p=0.0613), (B) WNT10B (r=-0.0041; p=0.9863), (C) COL1A1 (r=-0.1157; p=0.5354), (D) DKK-1 (r=-0.0947; p=0.6522) mRNA levels. Data showed positive correlations between fasting glucose levels (mg/dl) with (E) AXIN2 (r=0.0993; p=0.6442), (F) BETA-CATENIN (r=0.2371; p=0.1991) and (G) SFRP5 (r=0.3767; p=0.0696). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.

Supplementary figure 2. Relationship between Young Modulus (MPa), Ultimate strength (MPa) and Yield strength (MPa) with mRNA levels of the Wnt signaling genes in T2D and non-diabetic subjects. (A) DKK-1 positively correlated with Young Modulus (MPa); (r=0.02857; p=0.9022). (B) COL1A1 positively correlated with Young Modulus (MPa); (r=0.2991; p=0.1397). (C) GSK3B negatively correlated with Young Modulus (MPa); (r=-0.3127; p=0.0814). (D) SOST negatively correlated with Ultimate strength (MPa); (r=-0.1468; p=0.4001). (E) DKK-1 negatively correlated with Ultimate strength (MPa); (r=0.1353; p=0.5694). (F) LEF-1 positively correlated with Ultimate strength (MPa); (r=0.2790; p=0.1588). (G) WNT5A negatively correlated with Ultimate strength (MPa); (r=-0.0143; p=0.9469). (H) COL1A1 positively correlated with Ultimate strength (MPa); (r=0.2138; p=0.3047). (I) GSK3B negatively correlated with Ultimate strength (MPa); (r=-0.3482; p=0.0594). (J) SFPR5 negatively correlated with Ultimate strength (MPa); (r=-0.3789; p=0.0994). (K) SOST positively correlated with Yield strength (MPa); (r=0.1009; p=0.6390). (L) DKK-1 positively correlated with Yield strength (MPa); (r=0.2786; p=0.3139). (M) WNT10B negatively correlated with

medRxiv preprint doi: https://doi.org/10.1101/2023.10.06.23296647; this version posted December 19, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY 4.0 International license .

Yield strength (MPa); (r=-0.0079; p=0.9744). (N) COL1A1 positively correlated with Yield strength (MPa); (r=0.2196; p=0.3260). (O) BETA-CATENIN negatively correlated with Young Modulus strength (MPa); (r=-0.1667; p=0.4953). (P) BETA-CATENIN negatively correlated with Ultimate strength (MPa); (r=-0.2797; p=0.2610). (Q) BETA-CATENIN negatively correlated with Yield strength (MPa); (r=-0.1813; p=0.5537). Data were analyzed using nonparametric Spearman correlation analysis and r represents the correlation coefficient.


A
SOST
p<0.0001
B
DKK-1
p=0.2022
C
LEF-1
p=0.0136
D
WNT10B
p=0.0302
E
WNT5A
p=0.0232
F
COL1A1
p=0.0482
G
GSK3B
p=0.0456
H
AXIN2
p=0.2296
I
BETA-CATENIN
p=0.3073
J
SFRP5
p=0.1390
mRNA expression level
T2D subjects
Non-diabetic subjects

Figure 1


A
LEF-1 (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=-0.7500
p=0.0255
B
COL1A1 (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=-0.9762
p=0.0004
C
SOST (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.9231
p<0.0001
D
WNT5A (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.6751
p=0.0322
E
WNT10B (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=-0.4883
p=0.1938
F
DKK-1 (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.0476
p=0.9349
G
GSK3B (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.7500
p=0.0255
H
SFRP5 (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.7167
p=0.0369
I
AXIN2 (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.5500
p=0.1328
J
BETA-CATENIN (mRNA expression levels)
AGEs (µg quinine/g collagen)
r=0.2167
p=0.5809

Figure 2


A
SOST
(mRNA expression levels)
0.05
0.04
0.03
0.02
0.01
0.00
0
50
100
150
200
Fasting glucose levels (mg/dl)
r=0.4846
p=0.0043
B
SOST
(mRNA expression levels)
0.05
0.04
0.03
0.02
0.01
0.00
0
10
20
30
Disease duration (years)
r=0.7107
p=0.0174
C
WNT6A
(mRNA expression levels)
0.025
0.020
0.015
0.010
0.005
0.000
0
50
100
150
200
Fasting glucose levels (mg/dl)
r=0.5589
p=0.0037
D
GSK3B
(mRNA expression levels)
3
2
1
0
0
50
100
150
200
Fasting glucose levels (mg/dl)
r=0.4901
p=0.0051

Figure 3


A
SOST (mRNA expression levels)
Young Modulus (MPa)
r=-0.5675
p=0.0011
B
LEF-1 (mRNA expression levels)
Young Modulus (MPa)
r=0.4116
p=0.0295
C
WNT10B (mRNA expression levels)
Young Modulus (MPa)
r=0.6697
p=0.0001
D
AXIN2 (mRNA expression levels)
Young Modulus (MPa)
r=-0.5523
p=0.0042
E
SFRP5 (mRNA expression levels)
Young Modulus (MPa)
r=-0.4442
p=0.0437
F
WNT10B (mRNA expression levels)
Ultimate strength (MPa)
r=0.5392
p=0.0054
G
AXIN2 (mRNA expression levels)
Ultimate strength (MPa)
r=-0.4180
p=0.0472
H
LEF-1 (mRNA expression levels)
Yield strength (MPa)
r=0.4338
p=0.0495
I
WNT10B (mRNA expression levels)
Yield strength (MPa)
r=0.6632
p=0.0020
J
GSK3B (mRNA expression levels)
Yield strength (MPa)
r=-0.4674
p=0.0245
K
AXIN2 (mRNA expression levels)
Yield strength (MPa)
r=-0.5067
p=0.0319
L
SFRP5 (mRNA expression levels)
Yield strength (MPa)
r=-0.5357
p=0.0422

Figure 4